Roivant Sciences Ltd. (ROIV)
NASDAQ: ROIV · Real-Time Price · USD
13.48
+0.57 (4.42%)
At close: Sep 9, 2025, 4:00 PM
13.49
+0.01 (0.07%)
Pre-market: Sep 10, 2025, 8:08 AM EDT
Roivant Sciences Employees
Roivant Sciences had 750 employees as of March 31, 2025. The number of employees decreased by 158 or -17.40% compared to the previous year.
Employees
750
Change (1Y)
-158
Growth (1Y)
-17.40%
Revenue / Employee
$30,977
Profits / Employee
-$654,177
Market Cap
9.21B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 750 | -158 | -17.40% |
| Mar 31, 2024 | 908 | 4 | 0.44% |
| Mar 31, 2023 | 904 | 41 | 4.75% |
| Mar 31, 2022 | 863 | 198 | 29.77% |
| Jun 30, 2021 | 665 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
ROIV News
- 1 day ago - Roivant Sciences Ltd. (ROIV) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 6 days ago - Pulmovant Receives Orphan Drug Designation in Japan for Mosliciguat for the Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD) - GlobeNewsWire
- 6 days ago - Roivant Sciences Ltd. - Immunovant Batoclimab Graves' Disease Proof-Of-Concept Study Remission Data Transcript - Seeking Alpha
- 6 days ago - Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients - GlobeNewsWire
- 25 days ago - Roivant Sciences: Vant Model And IMVT-1402 Create A 2025 Catalyst Stack - Seeking Alpha
- 4 weeks ago - Roivant Sciences Ltd. (ROIV) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 weeks ago - Roivant Reports Financial Results for the First Quarter Ended June 30, 2025, and Provides Business Update - GlobeNewsWire
- 6 weeks ago - Roivant to Report Financial Results for the First Quarter Ended June 30, 2025, and Provide Business Update on Monday, August 11, 2025 - GlobeNewsWire